Please ensure Javascript is enabled for purposes of website accessibility

Arena Pharmaceuticals' Shares Slid 13% in April: Can the Stock Bounce Back?

By George Budwell - May 6, 2016 at 3:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Arena's stock turns in another bad month. Is it finally time to start buying?

ARNA Chart

ARNA data by YCharts

What: Shares of Arena Pharmaceuticals (ARNA) fell by more than 13% last month, according to data from S&P Global Market Intelligence. The biotech's monthly plunge seems to stem from the updated prescription numbers from IMS Health for the company's anti-obesity pill Belviq, showing that the drug's commercialization failed to build any positive momentum in the first quarter of 2016.  

Source: Arena Pharmaceuticals 

So what: The Street is expecting Arena's top-line to decline by roughly 26% year over year when the company reports its first quarter earnings on May 9 due in no small part to Belviq's flagging sales. 

Now what: Arena and its fellow anti-obesity drugmakers have struggled mightily in their collective efforts to commercialize this latest cohort of FDA approved weight loss medicines. Unfortunately, the combination of weak patient demand and the apparent unwillingness of doctors to prescribe these drugs is proving to be a tough nut to crack, devastating Arena's two closest competitors in the process.

In response to Belviq's tepid sales, Arena has attempted to shift investors' attention to its promising clinical-stage pipeline that sports the experimental pain medicine APD371, and the autoimmune disorder drug candidate APD334. The bad news, though, is that this strategy implies that Arena will remain cash flow negative for the foreseeable future, given that APD371 and APD334 are both several years away from even entering a pivotal stage trial.

Another major issue to consider is the potential for Belviq's marketing partner, Eisai (ESALY 1.38%), to terminate its partnership with Arena as a result of the drug's flattening sales trajectory. If Eisai did decide to cut its losses on Belviq, Arena would be solely responsible for the drug's commercialization, which the drugmaker frankly doesn't have the resources to handle. So, my take is that investors are probably best served by watching this speculative biotech from the safety of the sidelines for the time being. 

A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arena Pharmaceuticals, Inc. Stock Quote
Arena Pharmaceuticals, Inc.
ARNA
Eisai Co., Ltd. Stock Quote
Eisai Co., Ltd.
ESALY
$42.58 (1.38%) $0.58

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.